chlorthalidone has been researched along with azilsartan in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bleske, BE; Dorsch, MP; Shuster, JE | 1 |
| Barrios, V; Escobar, C | 1 |
| Jin, C; Kleven, DT; O'Boyle, S; Pollock, DM; Pollock, JS; White, JJ | 1 |
| Bala, V; Bhateria, M; Bhatta, RS; Puttrevu, SK; Ramakrishna, R; Sharma, VL | 1 |
| van der Merwe, WM | 1 |
| Athanasiadi, E; Katsi, V; Tousoulis, D; Tsioufis, C | 1 |
| Barakat, M; Bell, A; Blavignac, J; Burrows, M; Cheng, W; Fils-Aimé, N; Goldenberg, R; Paron, E | 1 |
| Barakat, M; Bell, A; Blavignac, J; Burrows, M; Cheng, W; Fils-Aimé, N; Goldenberg, R; Parron, E | 1 |
3 review(s) available for chlorthalidone and azilsartan
| Article | Year |
|---|---|
Clinical utility of azilsartan-chlorthalidone fixed combination in the management of hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Blood Pressure; Chlorthalidone; Diuretics; Drug Combinations; Humans; Hypertension; Oxadiazoles; Treatment Outcome | 2012 |
Azilsartan medoxomil in the treatment of hypertension: the definitive angiotensin receptor blocker?
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Chlorthalidone; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypertension; Oxadiazoles | 2013 |
Azilsartan and Chlorthalidone-new Powerful Fixed dose Antihypertensive Combination.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Arterial Pressure; Benzimidazoles; Chlorthalidone; Diuretics; Drug Combinations; Humans; Hypertension; Oxadiazoles; Treatment Outcome | 2018 |
5 other study(ies) available for chlorthalidone and azilsartan
| Article | Year |
|---|---|
Antihypertensive and anti-inflammatory actions of combined azilsartan and chlorthalidone in Dahl salt-sensitive rats on a high-fat, high-salt diet.
Topics: Animals; Anti-Inflammatory Agents; Antihypertensive Agents; Arterial Pressure; Benzimidazoles; Chlorthalidone; Diet, High-Fat; Drug Therapy, Combination; Inflammation; Kidney; Male; Oxadiazoles; Rats; Rats, Inbred Dahl; Sodium Chloride, Dietary | 2014 |
Simultaneous determination of azilsartan and chlorthalidone in rat and human plasma by liquid chromatography-electrospray tandem mass spectrometry.
Topics: Animals; Benzimidazoles; Chlorthalidone; Chromatography, Liquid; Humans; Linear Models; Male; Oxadiazoles; Protein Binding; Rats; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2015 |
Treatment of hypertension in CKD patients with azilsartan/chlorthalidone vs olmesartan/hydrochlorothiazide.
Topics: Antihypertensive Agents; Benzimidazoles; Chlorthalidone; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Olmesartan Medoxomil; Oxadiazoles; Renal Insufficiency, Chronic; Tetrazoles | 2018 |
Regional variability in Canadian routine care of type 2 diabetes, hypercholesterolemia, and hypertension: Results from the The Cardio-Vascular and metabolic treatments in Canada: Assessment of REal-life therapeutic value (CV-CARE) registry.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Benzimidazoles; Canada; Chlorthalidone; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypercholesterolemia; Hypertension; Hypoglycemic Agents; Male; Metformin; Middle Aged; Oxadiazoles | 2020 |
Real-world effectiveness of treatments for type 2 diabetes, hypercholesterolemia, and hypertension in Canadian routine care - Results from the CardioVascular and metabolic treatment in Canada: Assessment of REal-life therapeutic value (CV-CARE) registry,
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Benzimidazoles; Canada; Cardiovascular Diseases; Chlorthalidone; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Female; Humans; Hypercholesterolemia; Hypertension; Hypoglycemic Agents; Male; Metabolic Syndrome; Metformin; Middle Aged; Oxadiazoles; Prospective Studies; Registries; Treatment Outcome | 2020 |